Search Within

Department of Medicine

Formats
  1. Journal Article (19550)
  2. Meeting Abstract (16038)
  3. Review (1146)
  4. Book Section (934)
  5. Editorial (604)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (234)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22289)
  2. Hematologic Malignancies, Division of (13262)
  3. Center for Hematologic Malignancies (11047)
  4. GSK Faculty (10634)
  5. Survivorship Research (9316)
  6. Division of Subspecialty Medicine (7525)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1131)
  3. Sergio Giralt (1068)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1016)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3721)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6456)
  2. Elsevier Inc. (4651)
  3. American Society of Hematology (4000)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2284)
  6. Nature Publishing Group (2109)

More Publishers

Results (39567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
    Journal Article

    Burton, H.; Boussi, L.; Nemirovsky, D.; Derkach, A.; Ciervo, J.; Famulare, C.; Chin, K. K.; Valtis, Y.; Yisraeli Salman, M.; Patel, K.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: Subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
    Correspondence

    Domingo-Doménech, E.; Bosi, B.; Illidge, T.; Horwitz, S.; Trümper, L.; Iyer, S.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Kim, W. S.
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; The number needed to treat (NNT) versus the number needed to harm (NNH)?
    Review

    van Akkooi, A. C. J.; Mandala, M.; Nathan, P.; Haydon, A.; Postow, M.; Rutkowski, P.
    EJC Skin Cancer (2025)

    Fulltext@MSK | Save
  • Multi-modality AI predictor of lung cancer immunotherapy treatment response of durable response (DR)
    Meeting Abstract

    Jiang, J.; Yu, H.; Gomez, D.; Veeraraghavan, H.
    Radiotherapy and Oncology (2025)

    Fulltext@MSK | Save
  • An advanced practice provider-led telehealth intervention for oncology patients at end-of-life
    Meeting Abstract

    Lauria, T.; Qualters, K.; Kapoor-Hintzen, N.; Rosa, W.; Epstein, A.; Levine, M.; Koo, D.; Egan, B.; Puccia, S.; Gandham, A.; more...
    Journal of Pain and Symptom Management (2025)

    Fulltext@MSK | Save
  • Integration of health-related values in oncology as a primary palliative care intervention
    Meeting Abstract

    Rosa, W.; Epstein, A.; Goldberg, J.; Cohen, A.; Rosen, R.; Desai, A.; Gilliland, J.; Nelson, J.
    Journal of Pain and Symptom Management (2025)

    Fulltext@MSK | Save
  • Should they stay or should they go? Antimicrobials at the end-of-life
    Meeting Abstract

    Pandey, S.; Wisniewski, R.; Newman, T.; Seo, S.; Shah, K.; Francis, S.; Rosa, W.
    Journal of Pain and Symptom Management (2025)

    Fulltext@MSK | Save
  • Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1
    Meeting Abstract

    Friedman, C. F.; Sullivan, R. J.; Tschernia, N.; Sonpavde, G. P.; Herrera, M.; He, K.; Bilusic, M.; Garralda, E.; Hernando-Calvo, A. H.; Silk, A. W.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase I study of AFNT-211, autologous CD4(+) and CD8(+) T cells engineered to express a high avidity HLA-A(*)11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors
    Meeting Abstract

    Basu, S. K.; Khan, B.; Payumo, F.; Wan, R.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R. S.; Lenz, H. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save